![]()
李乾斌
— 博士生导师
分享到：
-
教师姓名：李乾斌
-
职称：教授
-
职务：博士生导师
-
教师拼音名称：liqianbin
-
所在单位：湘雅药学院
-
学历：博士研究生毕业
-
入职时间：2010-04-22
-
学位：博士学位
-
毕业院校：山东大学
-
在职信息：在职
-
学科：药学
-
招生学科：药学
- Hu L., Zhao R., Liu Q., Li Q. New Insights Into Heat Shock Protein 90 in the Pathogenesis of Pulmonary Arterial Hypertension. Front. Physiol., 2020, 11: 1081.
- Huang P., Le X., Huang F., Yang J., Yang H., Ma J., Hu G., Li Q., Chen Z. Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homologue Inhibitor via Structural Modification on Apcin. J Med Chem, 2020, 63(9): 4685-4700.
- Liu R., Yu Z., Chen Z., Liu D., Huang F., Li Q., Hu G., Yi X., Li X., Zhou H., Liu Z. A novel dual MEK/PDK1 inhibitor 9za retards the cell cycle at G0/G1 phase and induces mitochondrial apoptosis in non-small cell lung cancer cells. PeerJ, 2020, 8: e9981.
- Zhou Z., Long J., Wang Y., Li Y., Zhang X., Tang L., Chang Q., Chen Z., Hu G., Hu S., Li Q., Peng C., Chen X. Targeted degradation of CD147 proteins in melanoma. Bioorg Chem, 2020, 105: 104453.
- Cao Y., Le X., Shi X., Hao C., Ma B., Chen Z., Hu G., Cao D., Li Q. Multistep virtual screening based identification of homeodomain-interacting protein kinase 2 inhibitors: An opportunity for treating Chronic Kidney Disease. Chemometrics and Intelligent Laboratory Systems, 2021, 219: 104440.
- Xiao Z., Peng Y., Zheng B., Chang Q., Guo Y., Chen Z., Li Q., Hu G. Design, synthesis, and biological evaluation of 1,2,4-oxadiazole-containing pyrazolo[3,4-b]pyridinones as a new series of AMPKa1beta1gamma1 activators. Arch Pharm (Weinheim), 2021, 354(7): e2000458.
- Guo Y., Jiang X., Chang Q., Xiao Z., Chen Z., Jiang D., Hu G., Li Q. Novel pyrazolo[3,4-b]pyridine derivatives: Synthesis, structure-activity relationship studies, and regulation of the AMPK/70S6K pathway. Arch Pharm (Weinheim), 2022, 355(7): e2100465.
- Hu L., Wang G., Zhao C., Peng Z., Tao L., Chen Z., Hu G., Li Q. Identification of selective homeodomain interacting protein kinase 2 inhibitors, a potential treatment for renal fibrosis. Bioorg Chem, 2022, 126: 105866.
- Hu L., Zhao C., Chen Z., Hu G., Li X., Li Q. An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition. Drug Discov Today, 2022, 27(5): 1457-1463.
- Hao C., Cao M., Ouyang H., Chen Z., Hu G., Li Q. Recent advances in the development of HIPK2 inhibitors as anti-renal fibrosis agents. Future Med. Chem., 2023, 15(5): 453-465.
教师个人主页
中南大学
访问量：次
返回首页